Navigation Links
Orexigen(R) Therapeutics Names Patrick Mahaffy to Board of Directors
Date:3/2/2009

SAN DIEGO, March 2 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX) today announced that Patrick Mahaffy has been appointed to the Company's Board of Directors to fill an existing vacancy on the board.

Mr. Mahaffy brings significant biotechnology and pharmaceutical executive management experience. He was the founder of Pharmion Corporation and served as its President and CEO from its inception through its acquisition eight years later. Under Mr. Mahaffy's leadership, Pharmion successfully acquired, developed and gained approval for several oncology products in the U.S. and Europe and achieved significant revenues and sustained growth from those products until its acquisition by Celgene Corporation for $2.9 billion in March 2008. Mr. Mahaffy is presently creating a new company dedicated to acquiring and developing oncology drug products.

"Patrick has a proven track record in successfully managing all facets of drug development and commercialization, and his experience will be incredibly valuable as we complete the Phase 3 program for Contrave, our lead obesity product candidate," said Eckard Weber, M.D., Executive Chairman and Interim President and CEO. "In addition, his knowledge and experience in strategic business development will be important as we continue to explore partnership opportunities and execute on broader business strategies."

Prior to co-founding Pharmion, Mr. Mahaffy was President and CEO of NeXagen, Inc. and its successor, NeXstar Pharmaceuticals Inc. from 1992 until 1999. He is credited for developing corporate partnerships with Eli Lilly and Co., Systemix/Sandoz, Schering AG and Becton, Dickinson and Co. He took NeXstar Pharmaceuticals public in 1994 and in 1995 acquired publicly-traded company Vestar. In July 1999, Gilead acquired NeXstar Pharmaceuticals for $800 million. Mr. Mahaffy received a B.A. from Lewis and Clark College and an M.A. from Columbia School of International Affairs.

About Orexigen(R) Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates targeted for obesity are Contrave, which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at http://www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
2. Orexigen(R) Therapeutics to Speak at J.P. Morgan Healthcare Conference
3. Prime Therapeutics Receives TIPPS Certification
4. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
5. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
6. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
7. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
8. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
9. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
10. Prime Therapeutics Announces URAC Accreditation
11. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... ... March is National Kidney Month – the perfect time to pause and thank ... Every day, two kidneys filter about 120 to 150 quarts of blood. Put another ... regulating fluid levels and blood pressure, supporting bone health and promoting red blood cell ...
(Date:3/23/2017)... ... March 23, 2017 , ... The StayWell Company announced ... The accreditation covers StayWell’s asthma, coronary artery disease, congestive heart failure, chronic obstructive ... that have excellent programs for the delivery and improvement of disease management and ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... educational training program owned and organized by HMP Communications Holdings, LLC, today announced ... for physicians within its nationwide network of wound centers interested in becoming Certified ...
(Date:3/23/2017)... CO (PRWEB) , ... March 23, 2017 , ... ... serving the families and businesses of the greater Fort Collins area, has unveiled ... in their ongoing community involvement program. Donations to this worthy cause may now ...
(Date:3/23/2017)... ... , ... After raising more than $1.135 million ($1,479,231 AUD) from nearly 20,000 ... in crowdfunding history, has established a U.S. Headquarters in New York City, FaceCradle USA, ... “We’re excited to be operating on U.S. shores, where most of our initial crowdfunding ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... , March 23, 2017  The U.S. Food ... (avelumab) for the treatment of adults and pediatric patients ... (MCC), including those who have not received prior chemotherapy. ... a rare, aggressive form of skin cancer. ... cancers, patients with a rare form called Merkel cell ...
(Date:3/23/2017)... DIEGO and VANCOUVER, British Columbia ... (NASDAQ: SPHS ) (the "Company" or "Sophiris"), ... the treatment of urological diseases, today announced that data ... evaluated the drug as a focal treatment for localized ... March 26, 2017 at the 32 nd Annual ...
(Date:3/23/2017)... , Mar. 23, 2017 Research and ... Devices Market 2017-2021" report to their offering. ... The global oxygen therapy devices ... 2017-2021. The report, Global Oxygen Therapy Devices Market ... inputs from industry experts. The report covers the market landscape and ...
Breaking Medicine Technology: